• Bradford Protein Assay Kit: Practical Guide

  2026-09-29

  The Bradford Protein Assay Kit (K4103) provides a rapid colorimetric method for measuring protein concentration in solution using a Coomassie G-250 reagent and BSA standards. It is appropriate for routine protein quantification in molecular biology, enzyme, and purification workflows, but samples with incompatible detergents, strong alkaline components, turbidity, or concentrations outside the validated range require additional evaluation.

• Chloroquine Pharmacogenomics: Evidence and Implications

  2026-09-29

  The 2023 review by Biswas and Sukasem consolidates evidence that CYP2C8, CYP3A5, CYP2D6, and related metabolic variation may alter chloroquine and hydroxychloroquine exposure, efficacy, and toxicity. Its main contribution is a risk-phenotype framework that connects ultra-rapid and poor metabolizer states with possible therapeutic failure or adverse effects while emphasizing that clinical implementation still requires stronger validation.

• Eldecalcitol, Endothelial Ferroptosis, and T2DOP

  2026-09-28

  A 2025 study identifies endothelial ferroptosis as a mechanistic link between the high-glucose/high-fat environment of type 2 diabetes and impaired bone vascular–osteogenic coupling. Its evidence supports an SOCE/O-GlcNAcylation pathway through which eldecalcitol reduces lipid oxidative injury, improves vascular responses, and preserves osteogenesis in type 2 diabetic osteoporosis models.

• PX-478 Reduced ASD-Like Behaviors After Prenatal Hypoxia

  2026-09-28

  In a prenatal-hypoxia rat model, postnatal PX-478 treatment improved several autism-like behavioral measures and altered hippocampal HIF-1α and PTEN protein levels, alongside lower serum VEGF. The findings connect hypoxia signaling with neurodevelopmental outcomes in this model, but do not establish efficacy in people or prove that the measured molecular changes caused the behavioral effects.

• From Mechanism to Measurement in Diabetic Nephropathy

  2026-09-27

  Phillygenin research highlights how inflammation and apoptosis intersect in diabetic kidney injury. This article examines how membrane-integrity-based fluorescent cell counting can strengthen preclinical interpretation—while clarifying what AO/PI staining can, and cannot, establish.

• CRISPR Screen Maps Brucella Host-Dependency Genes

  2026-09-26

  A genome-wide CRISPR knockout screen in human THP-1 macrophages nominated host genes that influence Brucella infection, with individual knockout validation highlighting TRAPPC2 as a broad restriction point. The findings connect TRAPPC2 deficiency with reduced autophagosome formation, lower macrophage apoptosis, and improved cell viability, while underscoring the need for validation in primary cells and in vivo models.

• Neticonazole Hydrochloride: Bench Workflow Guide

  2026-09-25

  Neticonazole Hydrochloride offers researchers an imidazole antifungal tool for superficial Candida workflows and an exploratory route into colorectal cancer research. This guide separates established topical-treatment context from proposed laboratory workflows, with practical controls for solvent, fungal-growth, and exosome assays.

• ALC-0159 PEG Lipid: Evidence and Use

  2026-09-25

  ALC-0159 is a PEG-conjugated lipid excipient used in lipid nanoparticle formulations for mRNA delivery. Research on membrane-destabilizing zwitterionic lipids reports improved antigen expression and reduced local reactogenicity in mice, but does not establish those effects as properties of ALC-0159 itself.

• Protease Inhibitor Cocktail in Lysosome Research

  2026-09-24

  Learn how a Protease Inhibitor Cocktail EDTA-Free can preserve lysosomal proteins during sample preparation without confusing protein stability with organelle repair. This article connects recent findings on TECPR1-mediated lysosomal membrane tubulation to practical choices for extraction, phosphorylation analysis, and downstream assays.

• Batimastat (BB-94): MMP Assay & Model Workflows

  2026-09-24

  Use Batimastat (BB-94) to probe broad-spectrum MMP activity in enzyme assays, matrix-remodeling studies, and preclinical tumor models. This workflow also outlines a cautious way to test extracellular MMP involvement in localized BDNF processing—without confusing that hypothesis with the reference study’s demonstrated furin-dependent findings.

• Anti Reverse Cap Analog (ARCA): Evidence & Use

  2026-09-23

  Anti Reverse Cap Analog is a Cap 0 in vitro transcription cap analog designed to favor correct-orientation incorporation into synthetic mRNA. Product information reports approximately twofold higher translation efficiency than conventional m7G cap analogs, while the cited oligodendrocyte study supports synthetic mRNA reprogramming—not a direct test of ARCA.

• Primidone, RIPK1, and ALS Biomarker Translation

  2026-09-23

  The reference study links elevated peripheral RIPK1 and IL-8 with amyotrophic lateral sclerosis and evaluates Primidone as a pharmacological tool for suppressing this disease-associated signal. Its combined SOD1G93A mouse and human cohort design provides a translational framework for connecting RIPK1 inhibition with motor outcomes and blood-based biomarker monitoring.

• Aprotinin in Protease-Controlled GRO-seq Workflows

  2026-09-22

  Aprotinin adds targeted serine-protease control to extraction workflows while the reference GRO-seq strategy improves sequencing efficiency through rRNA depletion. This article connects practical BPTI handling with nuclear RNA profiling, cardiovascular blood-management research, and troubleshooting decisions that protect assay interpretability.

• Aprotinin (BPTI) for Cell Assays

  2026-09-22

  A practical, scenario-based guide to using Aprotinin (Bovine Pancreatic Trypsin Inhibitor, BPTI), SKU A2574, when protease activity may compromise cell viability, proliferation, or cytotoxicity assays. It connects mechanism, formulation, controls, data interpretation, and vendor-selection decisions to cited biochemical and biophysical evidence.

• GPNMB Model Predicts ESCC Immunotherapy Response

  2026-09-21

  This study identifies circulating soluble GPNMB as a mechanistically informative biomarker of resistance to PD-1 blockade in esophageal squamous cell carcinoma. By integrating plasma GPNMB, CAF-Epi niche features, and clinicopathological variables, the authors developed and validated a multimodal model with potential value for precision immunotherapy stratification.

8760 records 1/584 page Next 12345 下5页 Last page